non-small cell lung cancer
Oncologists Bemoan 'Lousy' PD-L1 Biomarker in Light of New Adjuvant Tecentriq NSCLC Study Data
Premium
Updated results from IMpower010 showed NSCLC patients with PD-L1 expression in 1 to 49 percent of tumor cells derived less benefit from adjuvant Tecentriq than those with higher expression.
New data for KRAS inhibitors in colorectal cancer show promising results when combined with EGFR inhibitors.
ESMO Data Shed Light on Activity of Janssen's Rybrevant-Leclaza Combo in EGFR-Mutated NSCLC
Analyses from CHRYSALIS and CHRYSALIS-2 trials suggest the benefit of adding the EGFR-TKI lazertinib to amivantamab including in heavily pretreated patients.
ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu
Premium
Studies showed that the antibody-drug conjugate benefited HER2-mutated NSCLC patients and outperformed Genentech's T-DM1 in HER2-positive, previously treated breast cancer.
Based on insights gleaned from earlier trials of its Granite and Slate neoantigen immunotherapies, the company is improving the design of its vaccines and homing in on best responders.